Digital Health Global

AUGUST 15, 2023

–(BUSINESS WIRE)– #Biotech –Taking a people-first approach, BioscienceLA, the ecosystem accelerator for life sciences in Greater Los Angeles, has launched its inaugural Leadership Catalyst Program for trailblazers in biotechnology and related sectors.

Life Science 88

Life Science Leadership BioTech Digital Health 88

Digital Health Global

OCTOBER 11, 2023

The acquisition immediately expands EVERSANA’s European operations and worldwide capabilities to help pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, or solve unique geographic and market-specific challenges. Financial details of the acquisition are not being disclosed.

Life Science 167

Life Science Pharmaceuticals BioTech Leadership 167

Lloyd Price

MAY 5, 2024

Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. The facility’s location will further EIT’s current partnerships in the Oxford biotech and technology communities, expand collaborations with the University of Oxford, and support the new Ellison Scholars programme.

healthcare technology 64

healthcare technology Leadership Life Science BioTech 64

Digital Health Global

MARCH 4, 2024

This is the second cohort for the One Mind Accelerator since the program’s launch in 2023. From digital health to biotech, from Pre-Seed to Series B, and from first-time founders to serial entrepreneurs, this cohort is indeed eclectic.

Mental health 88

Mental health BioTech Digital Health Psychiatry 88

Digital Health Global

FEBRUARY 7, 2023

3CC prioritizes early-stage investments in “Third Culture entrepreneurs” whose unique perspectives have the potential to help transform healthcare and address health disparities by optimizing care delivery in healthtech and biotech. Ciba Health was recently named among NY Digital Health 100 winners for 2023.

Chronic pain management 88

Chronic pain management BioTech Pain management Healthcare Innovation 88

Digital Health Global

MAY 8, 2023

The transaction is expected to close in the second half of 2023, subject to receipt of customary regulatory approvals and satisfaction of other customary closing conditions. For the full fourth quarter 2023, Baxter estimates the transaction to result in dilution of approximately $0.10 Advent International Inc.

Pharmaceuticals 88

Pharmaceuticals Life Science BioTech Leadership 88